Epirubicin
Back to searchMolecule Structure
Scientific Name
Epirubicin
Description of the Drug
Epirubicin is an anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00445
http://www.drugbank.ca/drugs/DB00445
Brand Name(s)
Not Available
Company Owner(s)
Actavis Totowa Llc, Impax Laboratories Inc, West-Ward Pharmaceuticals International Ltd, Fresenius Kabi Usa Llc, Hospira Inc, Pfizer Inc, Ebewe Pharma Ges Mbh Nfg Kg, Mylan Institutional Llc, Zennova Pharmaceuticals Chengdu Co Ltd, Akorn Operating Co Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8582 | ||
| PharmGKB | PA449476 | ||
| Human Metabolome Database | HMDB0014588 | ||
| WDI | EPIRUBICI | ||
| DrugBank | DB00445 | ||
| PubChem: Thomson Pharma | 14837077 | 14812446 | |
| PubChem | 41867 | ||
| LINCS | LSM-2078 | ||
| Nikkaji | J81.933F | ||
| BindingDB | 43839 | ||
| EPA CompTox Dashboard | DTXSID0022987 | ||
| DrugCentral | 1030 | ||
| Metabolights | MTBLC47898 | ||
| GSRS | 4f0a4a62-6657-47f4-b12d-9726d36e34c2 | ||
| rxnorm | EPIRUBICIN | EPIRUBICIN HYDROCHLORIDE | ELLENCE |
| KEGG Ligand | C11230 | ||
| ChEBI | 47898 | ||
| ZINC | ZINC000003938704 |
